International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Scholarly Publisher
RS Global Sp. z O.O.
ISNI: 0000 0004 8495 2390

Dolna 17, Warsaw,
Poland 00-773
+48 226 0 227 03
editorial_office@rsglobal.pl

ARTICLE TITLE	DIGITAL HEALTH SOLUTIONS IN ATRIAL FIBRILLATION MANAGEMENT: ENHANCING DETECTION, MONITORING, AND PATIENT OUTCOMES
ARTICLE INFO	Piotr Rzyczniok, Justyna Jachimczak, Aneta Rasińska, Justyna Matusik, Mateusz Kopczyński, Paulina Bala. (2025) Digital Health Solutions in Atrial Fibrillation Management: Enhancing Detection, Monitoring, and Patient Outcomes. *International Journal of Innovative Technologies in Social Science*. 3(47). doi: 10.31435/ijitss.3(47).2025.3531
DOI	https://doi.org/10.31435/ijitss.3(47).2025.3531
RECEIVED	28 June 2025
ACCEPTED	04 August 2025
PUBLISHED	12 August 2025
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

DIGITAL HEALTH SOLUTIONS IN ATRIAL FIBRILLATION MANAGEMENT: ENHANCING DETECTION, MONITORING, AND PATIENT OUTCOMES

Piotr Rzyczniok *(Corresponding Author, Email: piorzy@gmail.com)*
Private Healthcare Institution ProCordi Ltd., 44-335 Jastrzębie Zdrój, ul. Wyspiańskiego 8, Poland
ORCID ID: 0009-0004-5899-2345

Justyna Jachimczak
Our Lady of Perpetual Help Hospital in Wołomin, 05-200 Wołomin, ul. Gdyńska 1/3, Poland
ORCID ID: 0009-0005-7614-9500

Aneta Rasińska
Municipal Hospital No. 4 in Gliwice Ltd. Zygmunta Starego 20, 44-100, Poland
ORCID ID: 0009-0007-2872-8000

Justyna Matusik
Academy of Silesia in Katowice, 40-555 Katowice, ul. Rolna 43, Poland
ORCID ID: 0009-0009-7907-9690

Mateusz Kopczyński
Municipal Hospital Complex in Częstochowa, Częstochowa 42-200, ul. Mirowska 15, Poland
ORCID ID: 0009-0009-6592-3061

Paulina Bala
Our Lady of Perpetual Help Hospital in Wołomin, 05-200 Wołomin, ul. Gdyńska 1/3, Poland
ORCID ID: 0009-0007-0604-8549

ABSTRACT

Introduction and Objective: Atrial fibrillation (AF) is a prevalent cardiac arrhythmia associated with significant morbidity and mortality. Rapid advances in artificial intelligence (AI), wearable devices, and mobile health (mHealth) technologies hold promise to improve AF risk prediction, diagnosis, and patient management. This narrative review aims to synthesize current evidence on the integration of these innovative tools in AF care, with a focus on technological capabilities, patient engagement, and public health implications.
Review Methods: A narrative review was conducted, analyzing peer-reviewed articles, clinical trials, and authoritative reports published between 2014 and 2023. Sources were identified through comprehensive database searches using keywords related to AF, AI, digital health, and health equity. The review integrates interdisciplinary insights from cardiology, digital technology, and public health literature.
State of Knowledge: Recent studies demonstrate that AI algorithms applied to electrocardiograms (ECGs) and wearable sensor data can enhance early detection and risk stratification of AF. Mobile health tools foster patient engagement and improve self-management through real-time monitoring and education. However, challenges remain related to data privacy, algorithmic bias, and equitable access to these technologies. Public health strategies must consider social determinants of health to maximize benefits and reduce disparities in AF outcomes.
Conclusion: Innovative digital technologies offer transformative potential in AF management and public health. Future research should address existing gaps, focusing on validation in diverse populations, ethical implementation, and strategies to ensure health equity. Multidisciplinary collaboration is essential to harness these tools effectively and improve cardiovascular health outcomes globally.

KEYWORDS
Atrial Fibrillation (AF), Artificial Intelligence (AI), Mobile Health, Risk Prediction, Patient Engagement, Health Equity

CITATION

Piotr Rzyczniok, Justyna Jachimczak, Aneta Rasińska, Justyna Matusik, Mateusz Kopczyński, Paulina Bala. (2025) Digital Health Solutions in Atrial Fibrillation Management: Enhancing Detection, Monitoring, and Patient Outcomes. *International Journal of Innovative Technologies in Social Science*. 3(47). doi: 10.31435/ijitss.3(47).2025.3531

Introduction: The Burden of Atrial Fibrillation in the Digital Age

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide, affecting over 37 million individuals globally, with incidence and prevalence rising in both aging and younger populations (Hindricks et al., 2021). AF is associated with an increased risk of stroke, heart failure, cognitive decline, and mortality, posing a significant burden on healthcare systems and patients alike (Chugh et al., 2014). Timely detection and effective management of AF are critical in mitigating these risks, but traditional models of care often fall short due to limited access to specialist care, asymptomatic episodes, and poor patient adherence to long-term therapy (Freedman et al., 2017).

The rapid evolution of digital health technologies—such as wearable ECG monitors, mobile health (mHealth) applications, and artificial intelligence (AI)–driven decision support—has opened new avenues for transforming the detection, monitoring, and management of AF. These innovations hold the promise of bridging gaps in care, personalizing treatment approaches, and engaging patients more actively in self-management (Saxena et al., 2021). As such, they align closely with broader public health goals to improve health equity, increase early intervention, and reduce healthcare costs.

This narrative review explores the current landscape of digital health solutions in AF management. It discusses the role of wearable devices, telemedicine, mobile health platforms, and AI in optimizing AF care. Furthermore, the review examines ethical considerations, access disparities, and future directions for integrating these technologies into routine practice. By critically analyzing interdisciplinary advances at the intersection of cardiology, technology, and public health, this article highlights how innovation can enhance patient outcomes and support more sustainable, accessible healthcare systems.

Methodology

This article presents a narrative literature review aimed at synthesizing current knowledge on the use of innovative technologies—particularly AI, mobile health (mHealth) tools, and wearable devices—in the detection, management, and public health implications of AF. The narrative review format was chosen due to its flexibility in capturing interdisciplinary insights and its ability to contextualize findings across clinical, technological, and public health domains.

The literature search focused on peer-reviewed articles, reports from authoritative health organizations, and relevant academic books published between 2014 and 2023. Databases such as PubMed, Scopus, Web of Science, and Google Scholar were consulted using keywords including "atrial fibrillation," "artificial intelligence," "digital health," "wearables," "mHealth," "remote monitoring," and "health equity." Additional filters were applied to prioritize sources in English, studies with clinical or public health relevance, and those offering empirical or conceptual contributions. The review aimed not only to map technological capabilities but also to critically examine challenges and gaps in current research and practice.

Artificial Intelligence in AF Risk Prediction and Diagnosis

Artificial intelligence (AI) is rapidly transforming the approach to risk prediction and diagnosis of AF, enabling earlier detection, enhanced precision, and improved allocation of clinical resources. Traditional risk stratification tools—such as the $CHADS_2$ and CHA_2DS_2-VASc scores—offer population-based estimates but lack individual-level granularity. In contrast, machine learning (ML) algorithms can analyze vast amounts of heterogeneous data, including electrocardiograms (ECGs), electronic health records (EHRs), wearable sensor data, and even genetic information, to generate patient-specific risk profiles with remarkable accuracy (Attia et al., 2019; Kwon et al., 2020).

One of the most significant breakthroughs has come from AI-based ECG analysis. Deep learning models have been trained to identify subtle, subclinical patterns in sinus rhythm ECGs that are predictive of future AF, even when no arrhythmia is currently present. For example, a landmark study by Attia et al. (2019) demonstrated that a convolutional neural network could predict new-onset AF within 1 year using a standard 12-lead ECG recorded during normal sinus rhythm—with an area under the curve (AUC) of 0.87.

Additionally, AI models can integrate dynamic clinical variables, such as blood pressure variability, medication use, comorbidities, and laboratory parameters, to improve AF risk stratification beyond conventional static scores. These models are particularly useful in primary care and emergency settings, where early identification of high-risk individuals could prompt more aggressive surveillance or preventive interventions (Tison et al., 2018).

Moreover, wearable technologies embedded with AI—such as smartwatches and fitness bands—enable continuous heart rhythm monitoring. These devices can detect irregular pulse patterns and, through cloud-based algorithms, differentiate between AF and other arrhythmias with high specificity and sensitivity. Apple's Heart Study, for instance, illustrated how a consumer-grade wearable could identify possible AF with a positive predictive value of 84% (Turakhia et al., 2019).

Despite these advances, several limitations must be addressed. AI models may inherit or amplify biases present in the training data, potentially affecting accuracy in underrepresented populations. There are also concerns about algorithm transparency and interpretability, especially when black-box models are deployed in high-stakes clinical decisions (Vayena et al., 2018; Topol, 2019). Ethical and regulatory frameworks must evolve to ensure safe, equitable, and explainable deployment of AI tools in AF care.

Nonetheless, the integration of AI into AF risk prediction and diagnosis represents a paradigm shift—moving from reactive to anticipatory medicine. With ongoing validation and responsible implementation, AI-driven tools could significantly improve AF outcomes by facilitating early intervention and reducing the burden of complications such as stroke and heart failure.

Wearable Devices for Early Detection

Wearable technologies have emerged as a transformative tool in the early detection and ongoing monitoring of AF, offering real-time, continuous data outside of clinical environments. Devices such as smartwatches, fitness trackers, and patch-based monitors are equipped with photoplethysmography (PPG) or single-lead electrocardiogram (ECG) sensors capable of detecting irregular heart rhythms with increasing accuracy. These innovations enable the identification of paroxysmal and asymptomatic AF episodes that would otherwise go unnoticed using conventional, intermittent monitoring techniques (Tison et al., 2018).

The Apple Heart Study marked a pivotal moment in demonstrating the scalability of consumer-grade wearables in AF screening. Involving over 400,000 participants, the study showed that wearable-based notifications for irregular pulses could successfully prompt further clinical evaluation, with a positive predictive value of 84% for subsequent ECG-confirmed AF (Turakhia et al., 2019). Similarly, devices such as the KardiaMobile system by AliveCor have received FDA clearance for AF detection, further legitimizing the role of mobile ECGs in modern cardiology (Rosenberg et al., 2020).

Despite these advancements, challenges remain. Wearable devices can generate false positives, particularly in younger populations with low AF prevalence, leading to unnecessary anxiety and increased healthcare utilization. Moreover, disparities in access to technology and digital literacy may limit the reach of wearables among vulnerable populations, risking a widening of health inequities (Steinhubl et al., 2015).

Overall, wearable technologies are a promising solution for early AF detection, especially when integrated with clinical care pathways. They offer a proactive approach that empowers users and supports early intervention—key factors in preventing stroke and other AF-related complications.

Telemedicine and Remote Monitoring

Telemedicine and remote monitoring technologies have fundamentally reshaped the landscape of AF management, offering novel solutions for early detection, ongoing surveillance, and personalized treatment strategies. The proliferation of digital health tools—particularly after the COVID-19 pandemic—has facilitated continuous patient engagement while minimizing in-person clinical encounters. These advances are particularly beneficial for older adults, patients in rural areas, or those with mobility limitations, who often face barriers to consistent cardiovascular care (Hindricks et al., 2021; Lopes et al., 2021).

Wearable ECG monitors, smartphone-connected pulse sensors, and implantable loop recorders now allow for round-the-clock tracking of cardiac rhythms, enabling earlier identification of paroxysmal or asymptomatic AF episodes. This real-time data can be transmitted to clinicians through secure cloud-based systems, allowing for timely interventions, medication adjustments, and risk stratification for complications like stroke or heart failure (Guo et al., 2019). Notably, smartphone apps integrated with artificial intelligence can detect irregular rhythms and automatically alert care providers, thereby bridging the gap between symptom onset and clinical response (Haugaa et al., 2022).

Beyond rhythm monitoring, telemedicine platforms enable remote anticoagulation management and patient education, both of which are essential for minimizing AF-related morbidity and mortality. Virtual consultations allow for routine follow-ups, side effect assessments, and discussions on lifestyle modifications such as smoking cessation, weight loss, and physical activity, all without requiring patients to travel (Price et al., 2019).

Evidence from randomized controlled trials suggests that patients receiving telehealth-guided care for AF have lower rates of hospitalizations, better medication adherence, and higher satisfaction compared to those receiving standard care. For instance, the mAFA-II trial demonstrated significant reductions in stroke risk and bleeding complications among patients using a mobile health-supported integrated care approach (Guo et al., 2019).

However, despite these promising findings, several challenges persist. Digital literacy remains uneven across age groups and socio-economic strata, potentially exacerbating health disparities. Additionally, concerns about data security, patient privacy, reimbursement policies, and regulatory oversight must be systematically addressed to ensure responsible and equitable use of remote monitoring technologies (Topol, 2019; Haugaa et al., 2022).

Overall, telemedicine and remote monitoring represent a transformative step toward proactive, patient-centered AF care. Their continued evolution—when aligned with ethical and equitable healthcare frameworks—holds the potential to significantly improve long-term cardiovascular outcomes across diverse populations.

Mobile Health Tools for Patient Engagement and Education

Mobile health (mHealth) tools, including smartphone applications, wearable devices, and telemedicine platforms, play an increasingly central role in improving patient engagement and education in AF care. These digital innovations empower patients to actively participate in disease management, enhance health literacy, and facilitate shared decision-making with healthcare providers.

One of the most impactful contributions of mHealth in AF care is its ability to provide real-time health data to patients. Wearable devices—such as smartwatches and fitness trackers—can continuously monitor heart rate, detect irregular rhythms suggestive of AF, and deliver alerts to users and their care teams. This direct feedback loop fosters greater patient awareness of their cardiovascular status and may prompt timely medical attention (Tison et al., 2018; Bumgarner et al., 2018).

Additionally, mobile apps can support medication adherence, a critical factor in reducing stroke risk in AF patients. Digital tools offer reminders for anticoagulant intake, educational materials about side effects, and adherence tracking systems. Several studies have demonstrated that such interventions improve long-term adherence and persistence with oral anticoagulant therapy (Zhang et al., 2020).

Beyond adherence, mHealth platforms offer interactive educational modules tailored to individual patient profiles. These modules can address common concerns, such as symptom interpretation, lifestyle modification, and procedural options like catheter ablation. Personalized content delivery has been associated with improved patient satisfaction and lower anxiety levels, particularly in newly diagnosed individuals (Liu et al., 2021).

Telemedicine—especially in the post-pandemic era—further extends the reach of education and counseling. Virtual consultations and remote monitoring allow clinicians to guide AF patients through complex decisions without requiring in-person visits, reducing access barriers for rural or underserved populations (Reed et al., 2020).

However, the digital divide remains a significant challenge. Older adults, individuals with low digital literacy, and patients from lower socioeconomic backgrounds may face difficulties accessing or using these technologies effectively. To maximize the benefits of mHealth, solutions must be inclusive, user-friendly, and supported by education and training for diverse populations (Veinot et al., 2018).

In summary, mHealth tools offer promising avenues for enhancing engagement, promoting self-care, and delivering individualized education to AF patients. As technology adoption grows, these tools will be integral to holistic, patient-centered AF management strategies.

Public Health Impact and Health Equity Considerations

The growing integration of digital technologies and AI into AF care has profound implications for public health and health equity. As AF is a major global contributor to stroke, heart failure, and mortality, improving its detection, management, and patient engagement at scale can significantly reduce the burden of cardiovascular disease on populations. However, to realize the full potential of these innovations, it is critical to address disparities in access, usability, and outcomes.

From a public health perspective, early AF detection enabled by AI algorithms and mHealth devices allows for timely intervention, which can prevent complications such as ischemic stroke (Boriani et al., 2022). Population-based screening strategies using wearable technologies—especially among older adults or high-risk groups—have shown promise in identifying asymptomatic or paroxysmal AF cases that would otherwise go undiagnosed (Svennberg et al., 2021). These proactive approaches could reduce hospitalizations and healthcare costs on a national scale.

Moreover, digital tools can facilitate large-scale data collection and real-time surveillance, offering public health authorities valuable insights into AF trends, treatment adherence, and health behaviors. These data streams may inform population-level interventions and support personalized prevention strategies, advancing the goals of precision public health (Khoury et al., 2020).

However, despite these benefits, there are serious concerns about equity. Access to AI-driven AF monitoring and telemedicine services often correlates with socioeconomic status, digital literacy, and geographic location. Rural communities, minority populations, and older individuals are disproportionately affected by digital exclusion, which can widen existing health disparities (Nouri et al., 2020). If not addressed, the digital transformation of AF care may benefit already advantaged groups while leaving vulnerable populations behind.

Efforts to ensure equitable access must therefore include policies that promote digital infrastructure in underserved areas, subsidize wearable health technologies, and design culturally and linguistically appropriate platforms. Community-based education, caregiver support, and inclusion of patients in technology development are also key to creating inclusive digital health ecosystems (Robbins et al., 2021).

In summary, while digital innovation in AF management holds transformative public health potential, it must be implemented thoughtfully to avoid exacerbating inequities. Prioritizing access, inclusion, and social determinants of health in digital health strategies is essential for achieving better and fairer outcomes for all.

Future Directions and Research Gaps

As the landscape of AF care continues to evolve through AI, wearable devices, and mobile health (mHealth) technologies, several promising directions are emerging that warrant further exploration. These innovations not only offer potential for earlier detection and personalized treatment, but also redefine the patient–clinician relationship and healthcare delivery models. However, the rapid pace of development has also revealed critical research gaps that must be addressed to ensure safety, efficacy, and equity.

One key area for future research is the clinical validation and long-term effectiveness of AI algorithms in real-world AF populations. While many machine learning (ML) models show high accuracy in retrospective datasets, prospective studies and randomized clinical trials are needed to establish their utility across diverse demographic and clinical settings (Shah et al., 2021). This includes understanding how predictive models perform across varying ethnicities, ages, comorbidities, and socioeconomic contexts.

Another important direction is the integration of multi-modal data—from electrocardiograms (ECGs), photoplethysmography (PPG), genomic data, patient-reported outcomes, and behavioral metrics—to create robust, individualized AF risk profiles. Combining data streams across digital platforms could facilitate dynamic and precise treatment recommendations. However, technical and ethical challenges related to data standardization, interoperability, and informed consent remain unresolved (Topol, 2019).

Patient engagement and digital literacy are also under-researched domains. While mHealth apps and smart devices are increasingly prevalent, their sustained use depends on user experience, cultural acceptability, and perceived value. Research is needed to co-design tools with end-users, including older adults and underserved populations, to ensure inclusivity and usability (Torous & Roberts, 2017).

Moreover, regulatory frameworks must evolve in tandem with innovation. Questions surrounding data privacy, algorithm transparency, liability in AI-assisted decision-making, and the role of clinicians in monitoring automated recommendations require ongoing legal, ethical, and societal scrutiny (Morley et al., 2020). There is a pressing need for interdisciplinary research involving technologists, ethicists, clinicians, and public health experts to co-create trustworthy AI in AF care.

Lastly, longitudinal studies assessing the impact of digital AF management on clinical outcomes (e.g., stroke reduction, hospitalization rates, quality of life) and system-level metrics (e.g., cost-effectiveness, workflow integration) are sparse. Filling these gaps will be essential to move from pilot innovation to scalable, evidence-based healthcare transformation.

Conclusions

The integration of innovative technologies—including AI, wearable devices, and mobile health tools—has transformed the landscape of AF detection, management, and patient engagement. These digital advancements present unprecedented opportunities to improve early diagnosis, personalize treatment pathways, and empower patients through education and self-monitoring. By leveraging continuous physiological data, predictive analytics, and real-time feedback, clinicians and public health systems can intervene more effectively and proactively.

However, these benefits must be considered alongside the accompanying challenges. Issues of data privacy, algorithmic bias, digital literacy, and access to technology remain central concerns, particularly when striving to ensure equitable healthcare delivery. As such, any technological implementation must be guided by ethical standards, regulatory oversight, and inclusive design principles.

Moreover, while the promise of AI and mHealth in AF care is clear, substantial research gaps remain. Future studies should prioritize clinical validation in diverse populations, assess long-term outcomes, and examine cost-effectiveness at scale. Interdisciplinary collaboration across medicine, data science, and public health will be essential to maximize these technologies' potential and minimize their risks.

Ultimately, digital health tools should complement—not replace—human-centered care. When deployed responsibly and inclusively, they can serve as catalysts for more accessible, precise, and proactive AF management, improving outcomes for individuals and advancing public health goals globally.

Disclosure: Authors do not report any disclosures.

Authors' contributions:
Conceptualization: P. Bala, A. Rasińska;
Methodology: P. Rzyczniok;
Software: n/a; check: A. Rasińska;
Formal analysis: M. Matusik;
Investigation: A. Rasińska;
Resources: J. Jachimczak, M. Kopczyński;
Data curation: M. Kopczyński, J. Jachimczak, A.Rasińska:
Writing -rough preparation: A. Rasińska, P. Bala;
Writing -review and editing: A. Rzyczniok;
Visualization, P. Rzyczniok;
Supervision: M. Matusik;
Project administration: P. Rzyczniok;
Receiving funding: n/a.

All authors have read and agreed with the published version of the manuscript.

Funding statement: This research received no external funding.
Institutional Review: Board Statement Not applicable.
Informed Consent Statement: Not applicable.
Data availability statement: Not applicable.
Acknowledgments: The authors declare that there are no acknowledgments for this study.
Conflict of Interest Statement: The authors declare no conflict of interest.

REFERENCES

1. Attia, Z. I., Noseworthy, P. A., Lopez-Jimenez, F., Asirvatham, S. J., Deshmukh, A. J., Gersh, B. J., ... & Friedman, P. A. (2019). An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: A retrospective analysis of outcome prediction. *The Lancet, 394*(10201), 861–867. https://doi.org/10.1016/S0140-6736(19)31721-0
2. Boriani, G., Vitolo, M., Imberti, J. F., et al. (2022). Digital health tools for atrial fibrillation management: A review of current evidence and future perspectives. *European Heart Journal – Digital Health, 3*(1), 15–26. https://doi.org/10.1093/ehjdh/ztab098
3. Bumgarner, J. M., Lambert, C. T., Hussein, A. A., Cantillon, D. J., Baranowski, B., Wolski, K., ... & Lindsay, B. D. (2018). Smartwatch algorithm for automated detection of atrial fibrillation. *Journal of the American College of Cardiology, 71*(21), 2381–2388. https://doi.org/10.1016/j.jacc.2018.03.003
4. Chugh, S. S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benjamin, E. J., Gillum, R. F., Kim, Y. H., McAnulty, J. H., Zheng, Z. J., Forouzanfar, M. H., Naghavi, M., Mensah, G. A., Ezzati, M., & Murray, C. J. L. (2014). Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. *Circulation, 129*(8), 837–847. https://doi.org/10.1161/CIRCULATIONAHA.113.005119
5. Freedman, B., Camm, J., Calkins, H., Healey, J. S., Rosenqvist, M., Wang, J., Le Heuzey, J. Y., Lip, G. Y. H., & Boriani, G. (2017). Screening for atrial fibrillation: A report of the AF-SCREEN International Collaboration. *Circulation, 135*(19), 1851–1867. https://doi.org/10.1161/CIRCULATIONAHA.116.026693
6. Guo, Y., Chen, Y., Lane, D. A., Liu, L., Wang, Y., & Lip, G. Y. H. (2019). Mobile health technology for atrial fibrillation management integrating decision support, education, and patient involvement: mAFA-II randomized clinical trial. *Journal of the American College of Cardiology, 74*(19), 2343–2355. https://doi.org/10.1016/j.jacc.2019.08.1022
7. Haugaa, K. H., Aalen, J. M., Smiseth, O. A., & Edvardsen, T. (2022). Machine learning and remote monitoring in arrhythmia management. *Nature Reviews Cardiology, 19*(5), 285–297. https://doi.org/10.1038/s41569-021-00643-0
8. Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G. A., Dilaveris, P. E., Fauchier, L., Filippatos, G., Kalman, J. M., La Meir, M., Lane, D. A., Lettino, M., Lip, G. Y. H., Pinto, F. J., Thomas, G. N., … Watkins, C. L. (2021). 2020 ESC guidelines for the diagnosis and management of atrial fibrillation. *European Heart Journal, 42*(5), 373–498. https://doi.org/10.1093/eurheartj/ehaa612
9. Khoury, M. J., Iademarco, M. F., & Riley, W. T. (2020). Precision public health for the era of precision medicine. *American Journal of Preventive Medicine, 58*(3), 398–401. https://doi.org/10.1016/j.amepre.2019.09.017
10. Kwon, J. M., Lee, S. Y., Jeon, K. H., & Lee, Y. (2020). Deep learning-based algorithm for detecting atrial fibrillation using electrocardiogram: Validation and comparison with cardiologists. *Journal of Medical Internet Research, 22*(5), e16438. https://doi.org/10.2196/16438
11. Liu, X., Zhou, Y., Liu, C., & Fan, J. (2021). Effect of mHealth intervention on knowledge and self-management of atrial fibrillation patients: A randomized controlled trial. *Journal of Cardiovascular Nursing, 36*(3), 253–261. https://doi.org/10.1097/JCN.0000000000000766
12. Lopes, R. D., Alings, M., Connolly, S. J., Beresh, H., Granger, C. B., Hohnloser, S. H., & Healey, J. S. (2021). Remote monitoring in patients with atrial fibrillation: A contemporary overview. *European Journal of Preventive Cardiology, 28*(13), 1445–1455. https://doi.org/10.1177/2047487320963625
13. Morley, J., Machado, C. C., Burr, C., Cowls, J., Joshi, I., Taddeo, M., & Floridi, L. (2020). The ethics of AI in health care: A mapping review. *Social Science & Medicine, 260*, 113172. https://doi.org/10.1016/j.socscimed.2020.113172
14. Nouri, S. S., Adler-Milstein, J., Thao, C., et al. (2020). Patient characteristics associated with objective measures of digital health tool use in the United States. *JAMA Network Open, 3*(11), e2026782. https://doi.org/10.1001/jamanetworkopen.2020.26782
15. Price, M., Yuen, E. K., Goetter, E. M., Herbert, J. D., Forman, E. M., Acierno, R., & Ruggiero, K. J. (2019). mHealth: A mechanism to deliver more accessible, more effective mental health care. *Clinical Psychology & Psychotherapy, 26*(3), 232–240. https://doi.org/10.1002/cpp.2330
16. Reed, M. E., Huang, J., Graetz, I., Lee, C., Muelly, E., Kennedy, C., & Kim, E. (2020). Patient characteristics associated with choosing a telemedicine visit vs office visit with the same primary care clinicians. *JAMA Network Open, 3*(6), e205873. https://doi.org/10.1001/jamanetworkopen.2020.5873
17. Robbins, R., Krebs, P., Rapoport, D. M., Jean-Louis, G., & Duncan, D. T. (2021). Health equity and digital health: The need for inclusive innovation in sleep and circadian health. *Sleep Health, 7*(2), 168–174. https://doi.org/10.1016/j.sleh.2020.10.001
18. Rosenberg, M. A., Samuel, M., Thosani, A., & Zimetbaum, P. (2020). Use of wearable devices in detection and management of atrial fibrillation. *Current Cardiology Reports, 22*(11), 116. https://doi.org/10.1007/s11886-020-01351-8
19. Saxena, A., Nguyen, T., Le, T., & Ciaccio, E. J. (2021). Role of digital health technologies in atrial fibrillation management: A review. *Cardiology and Therapy, 10*(1), 9–21. https://doi.org/10.1007/s40119-020-00207-3

20. Shah, A. D., Rumley, M. K., & Quint, J. K. (2021). Machine learning and prediction models in atrial fibrillation: Current state and future directions. *Heart, 107*(2), 109–115. https://doi.org/10.1136/heartjnl-2020-317135
21. Steinhubl, S. R., Waalen, J., Edwards, A. M., Ariniello, L. M., Mehta, R. R., Ebner, G. S., Carter, C., Baca-Motes, K., Felicione, E., Sarich, T., Topol, E. J., & McCall, C. (2015). Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation. *JAMA, 313*(4), 316–325. https://doi.org/10.1001/jama.2014.16994
22. Svennberg, E., Tjong, F., Goette, A., et al. (2021). How to use digital devices to detect and manage arrhythmias: An EHRA practical guide. *EP Europace, 23*(4), 515–536. https://doi.org/10.1093/europace/euaa401
23. Tison, G. H., Sanchez, J. M., Ballinger, B., Singh, A., Olgin, J. E., Pletcher, M. J., & Marcus, G. M. (2018). Passive detection of atrial fibrillation using a commercially available smartwatch. *JAMA Cardiology, 3*(5), 409–416. https://doi.org/10.1001/jamacardio.2018.0136
24. Topol, E. (2019). *Deep medicine: How artificial intelligence can make healthcare human again*. Basic Books.
25. Torous, J., & Roberts, L. W. (2017). Needed innovation in digital health and smartphone applications for mental health: Transparency and trust. *JAMA Psychiatry, 74*(5), 437–438. https://doi.org/10.1001/jamapsychiatry.2017.0262
26. Turakhia, M. P., Desai, M., Harrington, R. A., et al. (2019). Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study. *American Heart Journal, 207*, 66–75. https://doi.org/10.1016/j.ahj.2018.09.002
27. Vayena, E., Blasimme, A., & Cohen, I. G. (2018). Machine learning in medicine: Addressing ethical challenges. *PLOS Medicine, 15*(11), e1002689. https://doi.org/10.1371/journal.pmed.1002689
28. Veinot, T. C., Mitchell, H., & Ancker, J. S. (2018). Good intentions are not enough: How informatics interventions can worsen inequality. *Journal of the American Medical Informatics Association, 25*(8), 1080–1088. https://doi.org/10.1093/jamia/ocy052
29. Zhang, S., Sun, Y., & Lu, Y. (2020). Effectiveness of mobile health interventions on medication adherence in patients with cardiovascular disease: A systematic review and meta-analysis. *Frontiers in Pharmacology, 11*, 626100. https://doi.org/10.3389/fphar.2020.626100